The effect of hydrochloric, malic and succinic salts of 2-ethyl-6-methyl-3-oxypyridine on ­self-­assessment of depression manifestations in women receiving radiotherapy after surgical ­treatment of uterine cancer

Abstract

Background. The detection of cancer and its subsequent treatment contribute to the development of depression. This circumstance illustrates the need for proactive prevention of affective status disorders in cancer patients, its dynamic control and timely correction.

Aim. Comparative analysis of the effect of hydrochloric, malic and succinic salts of 2-ethyl-6-methyl-3-oxypyridine (methylethylpyridinol, ethylmethylhydroxypyridine malate, ethylmethylhydroxypyridine succinate) on the dynamics of self-assessment of depression manifestations in women recieving radiation therapy after surgical treatment of uterine cancer.

Material and methods. A short-term, prospective, simple “blind”, placebo-controlled, randomized study of the effect of methylethylpyridinol, ethylmethylhydroxypyridine malate and ethylmethylhydroxypyridine succinate on the severity of depression symptoms in patients receiving radiation therapy after extended extirpation of the uterus with appendages was performed. The study was completed by 96 patients. Course two-week administration of drugs in almost equimolar single doses (0.83–0.88 mmol) was started simultaneously with radiation therapy. The treatment effectiveness was assessed using the Beck Depression Inventory 2 and 4 weeks after the start of the study. Statistical comparison of related samples was carried out using the Friedman test and post hoc analysis using the paired Wilcoxon test with the Bonferroni correction. Independent samples were compared using the Kruskal–Wallis test with a post hoc analysis using the Dan–Bonferroni test.

Results. Radiation therapy was found to cause a clinically significant increase in the severity of depressive symptoms in 14 and 28 days after the start of the study (p ≤0.010). Two-week administration of methylethylpyridinol, ethylmethylhydroxypyridine malate, and ethylmethylhydroxypyridine succinate reduced the severity of depressive symptoms to the normal level (p <0.001), mainly due to a decrease in the severity of symptoms of the cognitive-affective cluster (p <0.001). The studied drugs with equal severity prevented the escalation of depression symptoms according to the Beck Depression Inventory (p ˃0.05).

Conclusion. Hydrochloric, malic and succinic salts of 2-ethyl-6-methyl-3-oxypyridine are equally effective in preventing the development of depression during postoperative radiation treatment of patients with ute-rine cancer.

Keywords

radiation therapy / depression / methylethylpyridinol / ethylmethylhydroxypyridine malate / ethylmethyl­hydroxypyridine succinate

References

[1] Grassi L. Psychiatric and psychosocial implications in cancer care: the agenda of psycho-oncology. Epidemiol Psychiatr Sci. 2020;29:89. DOI: 10.1017/S2045796019000829.

[2] Zubkova YuN, Kurmukov IA, Obukhova OA, Kashia ShR. The relevance of the use of psychotropic drugs in clinical oncology. Pharmateka. 2018;(12):14–20. (In Russ.) DOI: 10.18565/pharmateca.2018.12.14-20.

[3] Зубкова Ю.Н., Курмуков И.А., Обухова О.А., Кашия Ш.Р. Актуальность применения психотропных препаратов в клинической онкологии. Фарматека. 2018;(12):14–20. DOI: 10.18565/pharmateca.2018.12.14-20.

[4] Kondratyeva KO, Semiglazova TYu, Kasparov BS, Vagaitseva MV, Klyuge VA. Antivital experiences of oncologic patients against the background of antitumor treatment and in the long term period. Pharmateka. 2020;27(7):76–80. (In Russ.) DOI: 10.18565/pharmateca.2020.7.76-80.

[5] Кондратьева К.О., Семиглазова Т.Ю., Каспаров Б.С., Вагайцева М.В., Клюге В.А. Антивитальные переживания онкологических больных на фоне противоопухолевого лечения и в отдалённом периоде. Фарматека. 2020;27(7):76–80. DOI: 10.18565/pharmateca.2020.7.76-80.

[6] Volchegorskii IA, Vazhenin AV, Zyuzina MS. The effect of derivatives of 3-hydroxypyridine and succinic acids on depressive symptoms, pain intensity and quality of life after surgical treatment of breast cancer. Journal of Modern Oncology. 2018;20(1):54–59. (In Russ.) DOI: 10.26442/1815-1434_20.1.54-59.

[7] Волчегорский И.А., Важенин А.В., Зюзина М.С. Влияние производных 3-оксипиридина и янтарной кислоты на депрессивную симптоматику, интенсивность боли и качество жизни после хирургического лечения рака молочной железы. Современная онкология. 2018;20(1):54–59. DOI: 10.26442/1815-1434_20.1.54-59.

[8] Volchegorskii IA, Mester KM. Effects of 3-hydroxypyridine and succinic acid derivatives on the dynamics of dorsalgia and affective disorders after surgical treatment of discs herniation. Eksperimentalnaya i klinicheskaya farmakologiya. 2010;73(1):33–39. (In Russ.) DOI: 10.30906/0869-2092-2010-73-1-33-39.

[9] Волчегорский И.А., Местер К.М. Влияние производных 3-оксипиридина и янтарной кислоты на динамику болевого синдрома и аффективных нарушений после удаления грыж межпозвонковых дисков. Экспериментальная и клиническая фармакология. 2010;73(1):33–39. DOI: 10.30906/0869-2092-2010-73-1-33-39.

[10] Volchegorskiy IA, Vazhenin AV, Zyuzina MS. Comparative analysis of the influence of 3-hydroxypyridine and succinic acid on the severity of pain and depressive symptoms after oncomammological intervention. Eksperimentalnaya i klinicheskaya farmakologiya. 2018;12(81):29–34. (In Russ.) DOI: 10.30906/0869-2092-2018-81-12-29-34.

[11] Волчегорский И.А., Важенин А.В., Зюзина М.С. Сравнительный анализ влияния производных 3-оксипиридина и янтарной кислоты на выраженность болевого синдрома и депрессивной симптоматики у пациенток после онкомаммологического вмешательства. Экспериментальная и клиническая фармакологи. 2018;12(81):29–34. DOI: 10.30906/0869-2092-2018-81-12-29-34.

[12] Dvoyrin VV, Klimenkov AA. Metodika kontroliruemykh klinicheskikh ispytaniy. (Method of controlled clinical trials.) Moscow: Meditsina; 1985. 143 p. (In Russ.)

[13] Двойрин В.В., Клименков А.А. Методика контролируемых клинических испытаний. М.: Медицина; 1985. 143 с.

[14] Avedisova AS, Chakhava VO, Lyupaeva NV. Placebo effect in psychiatry (literature review). Russian journal of psychiatry. 2003;(3):65–71. (In Russ.)

[15] Аведисова А.С., Чахава В.О., Люпаева Н.В. Плацебо-эффект в психиатрии (обзор литературы). Российский психиатрический журнал. 2003;(3):65–71.

[16] Belova AN. Shkaly, testy i oprosniki v nevrologii i neyrokhirurgii. (Scales, tests and questionnaires in neurology and neurosurgery.) 3rd ed. M.: Prakticheskaya meditsina; 2018. 696 p. (In Russ.)

[17] Белова А.Н. Шкалы, тесты и опросники в неврологии и нейрохирургии. Изд. 3-е, перераб. и доп. М.: Практическая медицина; 2018. 696 с.

[18] Andryushchenko AV, Drobizhev MYu, Dobrovol'skiy AV. Comparative evaluation of the CES-D, BDE and HADS(d) scale in the diagnosis of depression in general medical practice. Zhurnal nevrologii i psikhiatrii im SS Korsakova. 2003;103(5):11–18. (In Russ.)

[19] Андрющенко А.В., Дробижев М.Ю., Добровольский А.В. Сравнительная оценка шкал CES-D, BDI и HADS (d) в диагностике депрессий в общемедицинской практике. Журнал неврологии и психиатрии им. С.С. Корсакова. 2003;103(5):11–18.

[20] Novik AA, Ionova TI, Kalyadina SA, Kishtovich AV. Symptom assessment in patients with hematological malignancies: discrepancies in estimation of symptom severity and symptom management efficacy between a patient and a physician. Clinical oncohematology. 2008;1(3):238–245. (In Russ.)

[21] Новик А.А., Ионова Т.И., Калядина С.А., Киштович А.В. Оценка симптомов у больных со злокачественными заболеваниями системы крови: расхождения в оценке выраженности симптомов и эффективности их лечения между врачом и пациентом. Клиническая онкогематология. Фундаментальные исследования и клиническая практика. 2008;1(3):238–245. EDN: JVKGHB.

[22] Смулевич А.Б. Депрессии при психических и соматических заболеваниях. Изд. 4-е, перераб. и доп. М.: Медицинское информационное агентство; 2015. 640 с. [Smulevich AB. Depressii pri psikhicheskikh i somaticheskikh zabolevaniyakh. (Depression in mental and somatic diseases.) 4th ed. Moscow: Meditsinskoe informatsionnoe agentstvo; 2015. 640 p.

[23] Holub K, Vargas A, Biete A. Radiation-induced lymphopenia: the main aspects to consider in immunotherapy trials for endometrial and cervical cancer patients. Clin Trans Oncol. 2020;22(11):2040–2048. DOI: 10.1007/s12094-020-02345-3.

[24] Volchegorskii IA, Miroshnichenko IYu, Rassohina LM, Faizullin RM. Experimental study of 3-oxypiridine and succinic acid derivates antidepressant activity in mice. Eksperimentalnaya i klinicheskaya farmakologiya. 2013;76(7):6–10. (In Russ.) DOI: 10.30906/0869-2092-2013-76-7-6-10.

[25] Волчегорский И.А., Мирошниченко И.Ю., Рассохина Л.М., Файзуллин Р.М. Исследование антидепрессивной активности производных 3-оксипиридина и янтарной кислоты в эксперименте на мышах. Экспериментальная и клиническая фармакология. 2013;76(7):6–10. DOI: 10.30906/0869-2092-2013-76-7-6-10.

[26] Volchegorskii IA, Sinitskii AI, Miroshnichenko IYu, Rassokhina LM. Effects of 3-hydroxypyridine and succinic acid derivatives on monoamine oxidase activity in vitro. Pharmaceutical Chemistry Journal. 2018;52(1):3–7. (In Russ.) DOI: 10.1007/s11094-018-1760-2.

[27] Волчегорский И.А., Синицкий А.И., Мирошниченко И.Ю., Рассохина Л.М. Влияние производных 3-оксипиридина и янтарной кислоты на активность моноаминоксидаз in vitro. Химико-фармацевтический журнал. 2018;52(1):3–7. DOI: 10.1007/s11094-018-1760-2.

RIGHTS & PERMISSIONS

Eco-Vector